KRAS and lung adenocarcinoma: In lung adenocarcinoma KRAS mutations are associated with poor prognosis and non-responsiveness to EGFR inhibitors whereas KRAS wild-type tumors with EGFR mutations are linked to better prognosis and response to EGFR inhibitors [10].